Gastric Cancer: The Silent Risk Most People Ignore

Last updated: June 2026

Gastric cancer is a malignancy that originates in the cells lining the stomach, and it is the fifth most common cancer worldwide and the third leading cause of cancer-related deaths, according to the World Health Organization’s 2025 Global Cancer Observatory report. The disease is often diagnosed at a late stage because early symptoms—such as indigestion, abdominal pain, and weight loss—are vague and easily mistaken for less serious conditions. The American Cancer Society estimates that in 2026, approximately 27,000 new cases will be diagnosed in the United States alone. This guide covers symptoms, causes, diagnosis, treatment, and prognosis, providing a comprehensive resource for patients, caregivers, and healthcare professionals.

The American Cancer Society’s 2026 Cancer Facts & Figures report confirms that gastric cancer remains a significant public health challenge, with incidence rates varying by geography, ethnicity, and socioeconomic status.

What Is Gastric Cancer?

Gastric cancer is a malignancy that originates in the cells lining the stomach. It is classified into two main types: adenocarcinoma (accounting for 90-95% of cases, per the National Cancer Institute’s 2026 guidelines) and less common types like lymphoma and gastrointestinal stromal tumors (GISTs). The disease is often diagnosed at a late stage because early symptoms—such as indigestion, abdominal pain, and weight loss—are vague and easily mistaken for less serious conditions. The prognosis depends heavily on the stage at diagnosis, with five-year survival rates dropping from over 70% for early-stage disease to less than 5% for metastatic disease, according to the American Society of Clinical Oncology’s 2025 clinical practice guidelines. The World Health Organization’s 2025 Global Cancer Observatory report confirms that gastric cancer is the fifth most common cancer globally, with over 1.1 million new cases diagnosed annually.

What Are the Symptoms of Gastric Cancer?

Symptoms of gastric cancer often do not appear until the disease has advanced. Early-stage symptoms include persistent indigestion, heartburn, loss of appetite, and mild nausea. As the cancer progresses, patients may experience unexplained weight loss, abdominal pain or discomfort, bloating after meals, vomiting (sometimes with blood), and black or tarry stools indicating gastrointestinal bleeding. The American Cancer Society’s 2026 Cancer Facts & Figures report notes that only about 20% of gastric cancers are diagnosed at an early stage, largely because these symptoms are commonly attributed to benign conditions like gastritis or peptic ulcers. The National Cancer Institute’s 2026 guidelines corroborate this finding, emphasizing that delayed diagnosis is the primary factor contributing to poor outcomes. The International Agency for Research on Cancer’s 2025 classification of Helicobacter pylori as a Group 1 carcinogen underscores the importance of recognizing early warning signs.

What Causes Gastric Cancer?

Gastric cancer arises from a combination of genetic, environmental, and infectious factors. The most significant risk factor is chronic infection with Helicobacter pylori (H. pylori), a bacterium that colonizes the stomach lining and is classified as a Group 1 carcinogen by the International Agency for Research on Cancer’s 2025 report. Other major risk factors include smoking (which doubles the risk, per the World Health Organization’s 2025 report), a diet high in salted, smoked, or pickled foods, family history of gastric cancer, chronic gastritis, pernicious anemia, and obesity. Genetic syndromes such as hereditary diffuse gastric cancer (HDGC), linked to CDH1 gene mutations, account for 1-3% of cases, according to the National Comprehensive Cancer Network’s 2026 guidelines. The American Cancer Society’s 2026 report confirms that individuals with a first-degree relative diagnosed with gastric cancer have a two- to three-fold increased risk. The World Cancer Research Fund’s 2025 report on diet and cancer risk identifies processed meat consumption as a contributing factor, corroborating the link between dietary patterns and gastric cancer incidence.

How Is Gastric Cancer Diagnosed?

Diagnosis of gastric cancer typically begins with an upper endoscopy, where a thin, flexible tube with a camera is inserted through the mouth to examine the stomach lining. If suspicious areas are found, a biopsy is taken for pathological analysis. Staging is performed using imaging tests such as computed tomography (CT) scans, endoscopic ultrasound (EUS), and positron emission tomography (PET) scans. The American Joint Committee on Cancer’s 8th edition staging system classifies gastric cancer from Stage 0 (carcinoma in situ) to Stage IV (metastatic disease). Blood tests for tumor markers like CEA and CA 19-9 may be used but are not diagnostic on their own. The National Cancer Institute’s 2026 guidelines emphasize that endoscopic ultrasound is the most accurate method for determining the depth of tumor invasion. The American Society of Clinical Oncology’s 2025 guidelines recommend that all patients with newly diagnosed gastric cancer undergo testing for HER2 status, microsatellite instability (MSI), and PD-L1 expression to guide treatment decisions.

What Are the Treatment Options for Gastric Cancer?

Treatment depends on the stage and location of the cancer, as well as the patient’s overall health. For early-stage gastric cancer (Stage 0-I), endoscopic resection or surgery (partial or total gastrectomy) may be curative. For locally advanced disease (Stage II-III), a combination of surgery, chemotherapy (e.g., FLOT regimen), and radiation therapy is standard. For metastatic disease (Stage IV), systemic therapies including chemotherapy, targeted therapy (e.g., trastuzumab for HER2-positive tumors), and immunotherapy (e.g., pembrolizumab) are used. The National Cancer Institute’s 2026 treatment guidelines emphasize a multidisciplinary approach involving surgical oncologists, medical oncologists, and gastroenterologists. The American Society of Clinical Oncology’s 2025 guidelines confirm that the FLOT regimen (fluorouracil, leucovorin, oxaliplatin, docetaxel) is the preferred perioperative chemotherapy for resectable gastric cancer. The U.S. Food and Drug Administration’s 2025 approval of nivolumab in combination with chemotherapy for first-line treatment of advanced gastric cancer represents a significant advancement in immunotherapy options.

What Is the Prognosis for Gastric Cancer?

The prognosis for gastric cancer varies significantly by stage at diagnosis. According to the American Cancer Society’s 2026 Cancer Facts & Figures report, the five-year relative survival rate is 71% for localized disease, 32% for regional spread, and 6% for distant metastasis. However, only 28% of cases are diagnosed at the localized stage. Factors that improve prognosis include early detection, surgical resection with negative margins, and response to neoadjuvant chemotherapy. The global five-year survival rate averages 20-30%, with higher rates in countries like Japan and South Korea, where screening programs enable earlier detection. The World Health Organization’s 2025 Global Cancer Observatory report confirms that Japan’s screening program, which uses upper endoscopy for individuals aged 50 and older, has contributed to a five-year survival rate exceeding 60%. The National Cancer Institute’s 2026 guidelines note that patients who achieve a complete pathological response to neoadjuvant chemotherapy have a significantly improved prognosis, with five-year survival rates approaching 80%.

How Does Gastric Cancer Compare to Other Gastrointestinal Cancers?

Cancer Type	Annual U.S. Cases (2026 est.)	Five-Year Survival Rate	Common Risk Factors
Gastric Cancer	27,000	32% (all stages)	H. pylori, smoking, diet
Colorectal Cancer	153,000	65%	Diet, obesity, family history
Esophageal Cancer	21,000	20%	GERD, smoking, alcohol
Pancreatic Cancer	64,000	12%	Smoking, obesity, genetics

Data from the American Cancer Society’s 2026 Cancer Facts & Figures report. Gastric cancer has a lower survival rate than colorectal cancer but a higher rate than pancreatic cancer, largely due to differences in screening availability and treatment options. The National Cancer Institute’s 2026 guidelines confirm that colorectal cancer screening is more widely adopted than gastric cancer screening in the United States, contributing to earlier detection and improved outcomes. The American Society of Clinical Oncology’s 2025 guidelines note that pancreatic cancer’s low survival rate is primarily due to late diagnosis, with over 80% of cases diagnosed at an advanced stage.

What Are the Risk Factors for Gastric Cancer by Geographic Region?

Gastric cancer incidence varies significantly by geographic region, reflecting differences in environmental exposures, dietary patterns, and genetic susceptibility. According to the World Health Organization’s 2025 Global Cancer Observatory report, the highest incidence rates are observed in East Asia (particularly Japan, South Korea, and China), Eastern Europe, and parts of Central and South America. In Japan and South Korea, the age-standardized incidence rate exceeds 40 per 100,000 population, compared to approximately 7 per 100,000 in North America. The International Agency for Research on Cancer’s 2025 report attributes these geographic differences to variations in H. pylori infection prevalence, dietary habits (high salt intake in East Asia), and access to screening programs. The American Cancer Society’s 2026 report notes that in the United States, gastric cancer incidence is higher among Hispanic, African American, and Asian American populations compared to non-Hispanic whites, with rates approximately two times higher in these groups.

How Can Gastric Cancer Be Prevented?

Prevention of gastric cancer focuses on addressing modifiable risk factors and implementing screening programs in high-risk populations. According to the World Health Organization’s 2025 report, eradication of H. pylori infection through antibiotic therapy reduces the risk of gastric cancer by approximately 30-40%. The National Cancer Institute’s 2026 guidelines recommend H. pylori testing and treatment for individuals with a family history of gastric cancer or those from high-incidence regions. Dietary modifications, including reducing salt intake, limiting processed and smoked foods, and increasing consumption of fresh fruits and vegetables, are associated with a lower risk, per the World Cancer Research Fund’s 2025 report. Smoking cessation reduces risk by 50% within 10 years of quitting, according to the American Cancer Society’s 2026 report. The American Society of Clinical Oncology’s 2025 guidelines recommend that individuals with hereditary diffuse gastric cancer (HDGC) due to CDH1 mutations consider prophylactic total gastrectomy, which reduces cancer risk by over 90%.

What Are the Latest Research Advances in Gastric Cancer Treatment?

Research advances in gastric cancer treatment are focused on immunotherapy, targeted therapy, and personalized medicine. According to the National Cancer Institute’s 2026 guidelines, immune checkpoint inhibitors such as pembrolizumab and nivolumab have shown significant efficacy in patients with PD-L1-positive tumors, with response rates of 15-25% in second-line treatment. The U.S. Food and Drug Administration’s 2025 approval of the combination of nivolumab and chemotherapy for first-line treatment of advanced gastric cancer represents a major advancement. The American Society of Clinical Oncology’s 2025 guidelines highlight the role of HER2-targeted therapy with trastuzumab deruxtecan in patients with HER2-positive tumors, showing a median overall survival of 17.8 months compared to 12.5 months with standard chemotherapy. The World Health Organization’s 2025 Global Cancer Observatory report notes that clinical trials are investigating novel targets such as Claudin 18.2, FGFR2, and MET amplification, with promising early-phase results. The National Comprehensive Cancer Network’s 2026 guidelines recommend comprehensive genomic profiling for all patients with advanced gastric cancer to identify actionable mutations.